Literature DB >> 7600086

Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study.

N Turjanski1, R Weeks, R Dolan, A E Harding, D J Brooks.   

Abstract

We have used PET to study striatal D1 and D2 receptor binding in 10 patients with either the choreic or akinetic-rigid variants of Huntington's disease and in three patients with other causes of chorea. Background rigidity and bradykinesia in choreic patients were scored with a four-point scale. PET studies showed a severe and parallel reduction of both striatal D1 and D2 receptor binding in Huntington's disease patients irrespective of their predominant phenotype (mean reduction 60%). Huntington's disease patients with rigidity showed more pronounced reduction of striatal D1 and D2 binding compared with those without rigidity. A case of chorea associated with systemic lupus erythematosus had normal D2 binding. These results suggest that the presence of chorea per se may not be determined by alterations in striatal dopamine receptor binding, but that rigidity in Huntington's disease is associated with severe striatal D1 and D2 receptor loss.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7600086     DOI: 10.1093/brain/118.3.689

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  27 in total

Review 1.  Aspects of PET imaging relevant to the assessment of striatal transplantation in Huntington's disease.

Authors:  L Besret; A L Kendall; S B Dunnett
Journal:  J Anat       Date:  2000-05       Impact factor: 2.610

Review 2.  Applications of positron emission tomography (PET) in neurology.

Authors:  Y F Tai; P Piccini
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

3.  Levels of error processing in Huntington's disease: a combined study using event-related potentials and voxel-based morphometry.

Authors:  Christian Beste; Carsten Saft; Carsten Konrad; Jürgen Andrich; Anne Habbel; Inga Schepers; Andreas Jansen; Bettina Pfleiderer; Michael Falkenstein
Journal:  Hum Brain Mapp       Date:  2008-02       Impact factor: 5.038

Review 4.  Positron emission tomography imaging of transplant function.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-10

Review 5.  Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease.

Authors:  H D Rosas; A S Feigin; Steven M Hersch
Journal:  NeuroRx       Date:  2004-04

Review 6.  PET/CT in diagnosis of movement disorders.

Authors:  Valentina Berti; Alberto Pupi; Lisa Mosconi
Journal:  Ann N Y Acad Sci       Date:  2011-06       Impact factor: 5.691

Review 7.  Huntington's disease: the coming of age.

Authors:  Mritunjay Pandey; Usha Rajamma
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

Review 8.  Basal ganglia volumetric studies in affective disorder: what did we learn in the last 15 years?

Authors:  R M Bonelli; H-P Kapfhammer; S S Pillay; D A Yurgelun-Todd
Journal:  J Neural Transm (Vienna)       Date:  2005-10-27       Impact factor: 3.575

9.  Tetrabenazine is neuroprotective in Huntington's disease mice.

Authors:  Hongyu Wang; Xi Chen; Yuemei Li; Tie-Shan Tang; Ilya Bezprozvanny
Journal:  Mol Neurodegener       Date:  2010-04-26       Impact factor: 14.195

10.  Corticostriatal dysfunction underlies diminished striatal ascorbate release in the R6/2 mouse model of Huntington's disease.

Authors:  Jenelle L Dorner; Benjamin R Miller; Emma L Klein; Alexander Murphy-Nakhnikian; Rachel L Andrews; Scott J Barton; George V Rebec
Journal:  Brain Res       Date:  2009-07-16       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.